CRISPR

CRISPR2-en.gata2a.i4

ID
ZDB-CRISPR-200821-13
Name
CRISPR2-en.gata2a.i4
Previous Names
  • sgRNA2 targets intron 4 (1)
Target
Sequence
5' - GGCCCATGCTTTTGCATTTT - 3'
ZFIN BLAST NCBI BLAST Ensembl UCSC BLAT
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
uob101 en.gata2a.i4
Expression
Gene expression in Wild Types + CRISPR2-en.gata2a.i4
No data available
Phenotype
Phenotype resulting from CRISPR2-en.gata2a.i4
No data available
Phenotype of all Fish created by or utilizing CRISPR2-en.gata2a.i4
Phenotype Fish Conditions Figures
ventral wall of dorsal aorta gata2b expression decreased amount, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 3 with image from Dobrzycki et al., 2020
pericardium edematous, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 6 with image from Dobrzycki et al., 2020
erythrocyte maturation disrupted, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 6 with image from Dobrzycki et al., 2020
neutrophil decreased amount, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 6 with image from Dobrzycki et al., 2020
dorsal aorta gata2a expression decreased distribution, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 2 with image from Dobrzycki et al., 2020
dorsal aorta runx1 expression decreased amount, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 3 with image,  Fig. 5 with image from Dobrzycki et al., 2020
myeloid cell development disrupted, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 6 with image from Dobrzycki et al., 2020
dorsal aorta runx1 expression decreased amount, abnormal en.gata2a.i4uob101/uob101 chemical treatment: 4,4'-diaminodiphenylmethane Fig. 5 with image from Dobrzycki et al., 2020
vascular endothelium gata2a expression decreased amount, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 2 with image from Dobrzycki et al., 2020
hematopoietic cell decreased amount, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 5 with image,  Fig. 6 with image from Dobrzycki et al., 2020
hematopoietic cell decreased amount, exacerbated en.gata2a.i4uob101/uob101 chemical treatment: 4,4'-diaminodiphenylmethane Fig. 5 with image from Dobrzycki et al., 2020
defense response to bacterium decreased occurrence, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 6 with image from Dobrzycki et al., 2020
thymus rag1 expression decreased amount, abnormal en.gata2a.i4uob101/uob101 standard conditions Fig. 4 with image from Dobrzycki et al., 2020
dorsal aorta runx1 expression decreased amount, abnormal en.gata2a.i4uob101/uob101 + MO1-gata2b standard conditions Fig. 5 with image from Dobrzycki et al., 2020
hematopoietic cell decreased amount, exacerbated en.gata2a.i4uob101/uob101 + MO1-gata2b standard conditions Fig. 5 with image from Dobrzycki et al., 2020
caudal hematopoietic tissue myb expression decreased amount, abnormal en.gata2a.i4uob101/uob101 + MO1-gata2b standard conditions Fig. 5 with image from Dobrzycki et al., 2020
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.